Drug for parenteral nutrition and detoxification

 

(57) Abstract:

The invention relates to medicine, more accurately to drug parenteral nutrition and can be used for parenteral nutrition and detoxification. The product contains low-molecular polyvinylpyrrolidone medical, alanine, arginine, aspartic acid, valine, histidine, glycine, glutamic acid, isoleucine, leucine, lysine, methionine, Proline, serine, tyrosine, threonine, tryptophan, phenylalanine, cysteine, potassium chloride, calcium chloride, magnesium chloride, metabisulfite sodium or potassium hydroxide,water for injections. Research has shown that the drug has a pronounced anabolic effect on the level of the best drugs parenteral nutrition, and additionally detoxification effect.

The invention relates to medicine and can be used as a drug bifunctional action.

The prototype is a drug linodes, comprising 13 amino acids, low molecular weight polyvinylpyrrolidone and D-sorbitol in a ratio of components, g/l: low-molecular Polyvinylpyrrolidone medical 30 L-alanine 4,8 L-arginine hydrochloride 4,8 L-valine 3,8 L-histidine hydrochloride 2,4 Gli is anin 5,4 D-sorbitol 50,0 Water for injection Up to 1 litre

Lack of lindeza is that it contains a complete set of amino acids, but only 13 of them.

The aim of the invention is to obtain a bifunctional drug action, including a full set of amino acids in optimal ratios and component detoxification action of low - molecular polyvinylpyrrolidone.

Protein deficiency hampers the specific treatment of both therapeutic and surgical patients, often makes it impossible to carry out operations such patients. The presence of intoxication, which is expressed in many pathological conditions, complicates the treatment of patients and is often the cause of fatal outcomes. The use of drugs as parenteral nutrition, and needed to relieve symptoms of intoxication, forcing you to enter patients large amounts of fluid, which is highly undesirable, especially for elderly patients and young children and patients suffering from cardiovascular diseases.

To facilitate protein synthesis in the body, you must have the entire set of amino acids (18). For this part of the preparation necessary to enter another 5 amino acids asparag is to enter into the composition of the drug glutamine, which has a high regulatory effect and significantly increases thus protein synthesis in the body. However, due to its instability in solution, glutamine cannot be entered directly into the product. To ensure the synthesis of glutamine in the body is necessary to enter in the composition of the drug increased amounts of glutamic acid and Proline.

Introduction to offer this composition of the medicinal product high amounts of glutamic acid and Proline leads to a significant increase in the synthesis of glutamine, more pronounced than the introduction of best foreign medicines Meridiana f, aminoplasmal 1-10, liamine standard plus. In the liver of animals after administration of these drugs found the following quantities of glutamine, micromol/g of tissue: the Proposed remedy 3.4 km Aminoplasmal 1-10 less than 0.2 Levain standard plus 1.2 Meridian f 2,2

The objective is achieved by the fact that drug, in addition to 13 amino acids and low-molecular polyvinylpyrrolidone impose an additional 5 amino acids: aspartic and glutamic acids, serine, tyrosine and cysteine. The optimal ratio of all amino acids. The amount of amino acids is increased to 90-130 g/L.


Amino acid composition of the medicinal product are balanced, i.e., contains a complete set of amino acids in L-form in optimal ratios for protein synthesis. The number of amino acids in the product (from 90 to 130 g/l) gives the best therapeutic effect. The intravenous administration of a medicinal product with a higher concentration of amino acids than the specified exceeds the tolerance of the organism, but in a more low - not achieved the desired anabolic effect and nitrogen balance is lower than in the control group.

Introduction to drug polyvinylpyrrolidone provides significant detoxication effect shown in experiment 2 models intoxication and in patients with renal-hepatic syndrome involving intoxication.

Introduction medicinal product allows no less than 2 times to reduce the number entered in the body fluid, which is very important in a number of pathological conditions, especially in burn disease, cardiovascular disease, the elderly and young children.

The drug is studied in the experiment, successfully passed the clinical study and allowed for medical use Pharmacological molecularly medical 2,5 Alanine 3.9 Arginine 5,76 Aspartic acid 0,9 Valine 6,75 Histidine 2,97 Glycine 2,07 Glutamic acid 9,45 Isoleucine 4,86 Leucine 11,43 Proline 12.6 Lysine 7,65 Methionine 3,57 serine 6,03 Tyrosine 0,0345 Threonine 4,68 Tryptophan 1,53 Cysteine 0.4 Phenylalanine 5,76 Potassium chloride 0.3 Calcium chloride 0.3 Magnesium chloride 0,003 Metabisulfite sodium of 0.1 Water for injection Up to 1 litre

Recipe 2, g/l: low-molecular Polyvinylpyrrolidone medical 30,0 Alanine 4,73 Arginine? 7.04 baby mortality Aspartic acid 1,0 Valine 8.25 Histidine 3.63 Glycine 2,53 Glutamic acid 11,55 Isoleucine 5,94 Leucine 13,97 Proline 15,4 Lysine 9,35 Methionine 4,29 serine 7,37 Tyrosine 0,042 Threonine 5,72 Tryptophan 1,87 Cysteine 0.45 Phenylalanine? 7.04 baby mortality Potassium chloride 0.35 Calcium chloride 0.35 Magnesium chloride 0,004 Metabisulfite sodium 0,15 Water for injection Up to 1 litre

Recipe 3, g/l: low-molecular Polyvinylpyrrolidone medical 35,0 of Analin 5,6 Arginine 8,32 Aspartic acid 1,3 Valine 9,75 Histidine 4,29 Glycine 3,0 Glutamic acid 13,65 Isoleucine 7,02 Leucine 16,57 Proline 18,2 Lysine 11,05 Methionine 5,07 serine 8,7 Tyrosine 0.05 Threonine 6,76 Tryptophan 2,27 Cysteine 0.5 Phenylalanine 8,32 Potassium chloride 0.5 Calcium chloride 0.5 Magnesium chloride 0,005 Metabisulfite sodium 0,2 Water for injection Up to 1 litre

Recipe 4, g/l: low-molecular Polyvinylpyrrolidone medical 30,0 Alanine 4,73 Arginine? 7.04 baby mortality Aspartic acid 1,10 Valine 8.25 Histidine 3.63 Glycine 2,53 Glutamic acid 11,55 Isoleucine 5,94 Leucine 13,97 Proline 15,4 Lysine 9,35 Methionine 4,29 serine 7,37 Tyrosine 0,042 Threonine 5,72 Tryptophan 1,87 Cysteine 0.45 Phenylalanine? 7.04 baby mortality Potassium chloride 0.35 Calcium chloride 0.35 Magnesium chloride 0,004 Metabisulfite sodium 0,15 Water for injee amino acids 1-alanine, 1-arginine hydrochloride, 1-valine, 1-histidine hydrochloride, glycine, 1-isoleucine, 1-leucine, 1 - lysine hydrochloride, 1-methionine, 1-Proline, 1-threonine, 1-tryptophan, 1-phenylalanine, low-molecular polyvinylpyrrolidone medical and water, characterized in that it additionally contains L-aspartic and L-glutamic acid, L-serine, L-tyrosine and L-cysteine, potassium chloride, calcium and magnesium chloride, sodium metabisulfite or potassium in the following ratio of components, g/l:

The low-molecular polyvinylpyrrolidone medical 25 - 35

1-alanine 3,9 - 5,6

1-arginine hydrochloride of 5.8 to 8.3

1-aspartic acid 0,9 - 1,3

1-valine 6,7 - 9,7

1-histidine hydrochloride 2,9 - 4,3

Glycine 2,1 - 3,0

1-glutamic acid 9.4 - 13,6

1-isoleucine 4,8 - 7,0

1-leucine 11,4 - 16,6

1-lysine hydrochloride 7,6 - 11,0

1-methionine 3,5 - 5,0

1-Proline 12,6 - 18,2

1-serine 6,0 - 8,7

1-tyrosine 0,0341 - 0,05

1-threonine 4,7 - 6,8

1-tryptophan 1,5 - 2,3

1-phenylalanine 5,8 - 8,3

1-cysteine 0,3 - 0,5

Potassium chloride 0.3 to 0.5

Calcium chloride 0,3 - 0,5

Magnesium chloride 0,003 - 0,005

Metabisulphite sodium or potassium 0,1 - 0,2

Water for injection Up to 1 l

 

Same patents:

FIELD: pharmaceutics.

SUBSTANCE: the innovation deals with manufacturing remedies to prevent wound suppuration based upon polymeric matrix and antimicrobial substance due to mixing components in solution, forming the film to obtain a powder-like medicinal form by providing the safety of antimicrobial activity of medicinal preparation. The obtained remedy is completely biodestructed in the body and requires no repeated operation on its removal after the end of tissue regeneration processes.

EFFECT: higher efficiency of manufacturing.

1 cl, 3 ex, 1 tbl

FIELD: organic synthesis.

SUBSTANCE: invention provides novel triterpenoid derivatives having general formula:

(I), wherein, as polymer carrier, are used water-soluble copolymers of N-vinylpyrrolidone with α,β-(methyl)acrylic acid alkyl esters and quaternary ammonium salts thereof having general formula: (II), in which formulas A represents triterpenoid residue belonging to series of acids: betulinic {1}, betulonic {2}, glycyrrhetinic {3}, glycyrrhisic {4}, ursolic {5}, ursonic {6}, oleanolic {7}, oleanonic {8}, meristothropic {9}, diketomeristothropic {10}, macedonic {11}, diketomacedonic {12},equinocystic {13}, or mixture of above-indicated carboxyl-containing triterpenoids, where R1 and R2 are hydrogen or methyl; R3 methyl or ethyl; R4 is C6-C16-alkyl; Hal is iodine, bromine, or chlorine atom; k = 65-95 mol %; l = 0.1-34 mol %; n = 0.5-5.4 mol %; molecular weight is equal to (7-100)·103. Polymer derivatives of above-defined triterpenoids are prepared by reaction of terpolymer II, wherein k = 65-95 mol %; l = 0.1-34 mol %; x = 1.0-34.9 mol %; R1-R4, Hal and molecular weight as above. Reaction is carried out in organic solvent at concentration of terpolymer 1 to 30%, concentration of triterpenoid 0.05 to 3.4%, and molar ratio of motif containing quaternary nitrogen to triterpenoid between 1 and 10. Products are isolated by removing solvent.

EFFECT: expanded synthetic possibilities.

FIELD: medicine, ophthalmology, pharmacology, pharmacy.

SUBSTANCE: invention proposes a new agent for applying in therapy of inflammatory diseases of eye anterior site, namely, the silver-containing preparation "Argogel" "Argogel" represents argovite dispersion in polyethylene oxide gel. The preparation shows an antibacterial and virucidal effect and gel base shows additional keratoplastic effect. Invention can be used in therapy of conjunctivitis and retina suppurative ulcers.

EFFECT: valuable medicinal properties of agent.

4 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: invention proposes a composition for treatment and storage of soft contact lens that comprises cetyl pyridinium chloride, polyethylene oxide of molecular mass 400 Da, ethylenediaminetetraacetic acid disodium salt, sodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate and water taken in the definite ratios by wt.-%. Invention provides reducing toxicity and enhances disinfecting and clearing properties of composition used for treatment and storage of soft contact lens.

EFFECT: improved and valuable properties of composition.

2 tbl, 3 ex

FIELD: otorhinolaryngology.

SUBSTANCE: method consists in that, once a day, maxillary sinus is punctured, washed with 0.01% betadine solution and, after that, 10 ml of 0.1% betadine solution is injected into sinus. Treatment course comprises 3-4 punctures.

EFFECT: increased acute sinusitis treatment efficiency in absence of general antibacterial therapy due to simultaneous action of betadine on bacterial and viral constituents of pathogenic microflora.

FIELD: medicine.

SUBSTANCE: method involves introducing means containing heavy elements into tumor and expose it to X-ray radiation. A heavy chemical element having number of 53, 55-83 is used. The means contains one or several of said elements with additional ligand introduced as iminodiacetic acid or its derivatives or crownethers or porphyrins and a water-soluble polymer. The means is introduced in systemic or direct way into tumor with following X-ray irradiation of power of 10-200 keV being applied.

EFFECT: increased photon therapy dose concentrated in tumor tissue with concurrently reduced radiation exposure upon the unaffected tissues.

4 cl, 4 dwg, 6 tbl

FIELD: medicine.

SUBSTANCE: the present innovation deals with ways for purifying blood plasma in burnt patients followed by applying the plasma obtained either while carrying out the next plasmapheresis or as independent transfusion medium. For this purpose, it is necessary to carry out plasmapheresis in burnt patients. Heparin should be added into plasma removed during plasmapheresis and, additionally, hemodesis, followed by incubation at +4° C for about 5-18 h, then it should be centrifuged for depositing cryoprecipitate. The innovation suggested enables to alter conditions of cryoprecipitation so, that it is possible to increase precipitation of fibrinogen and fibrin-monomeric complexes, the quantity of which is sharply observed in burnt patients.

EFFECT: higher efficiency of purification.

1 tbl

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical composition and a method for it preparing. The composition comprising effective doses of hyaluronic acid, glycyrrhetinic acid as active components and polyvinylpyrrolidone is used in treatment of morbid inflammatory and ulcerous states of moisture epithelial surfaces, such as mucosa inflammation and Behchet's syndrome. The composition shows favorable effect due to its moistening action.

EFFECT: valuable medicinal and pharmaceutical properties of composition.

6 cl, 3 ex

FIELD: medicine.

SUBSTANCE: method involves administering intravenous hemodesis injections at a dose of 200 ml every other day as a part of traditional therapy after having studied patient immunity status. The total treatment course requires 600-1000 ml for 3-5 infusions. Rusam is concurrently administered at a dose of 20 mg once a day with 4-5 days long pauses. The total treatment course requires 600-800 mg of the drug.

EFFECT: enhanced effectiveness of selective treatment directed to given immune system chains.

FIELD: abdominal surgery.

SUBSTANCE: invention relates to manufacturing prostheses for abdominal surgery based on synthetic polymeric complex threads with coating, whose composition, in order to impart antimicrobial properties to allotransplant, is completed with various-type chemiotherapeutical materials, in particular antiseptic substance (Poviargol). Prosthesis of invention is designed for plastics of hernial defects of abdominal wall. Mesh prosthesis with antimicrobial properties for hernioplasty is manufactured as follows: polymeric composite consisting of (i) Poviargol substance, which is metal-polymer composition of ultrafine metallic silver stabilized with synthetic polymer Collidon, 40-45%, and (ii) medical-grade high-molecular weight polyvinylpyrrolidone, 55-60%, is applied onto synthetic polymer mesh, after which mesh with dispersion applied thereon is dried by way of blowing with hot air (60-80°C) for 20-30 min.

EFFECT: simplified manufacturing procedure and enhanced antimicrobial efficiency.

2 tbl, 8 ex

Up!